Wellington Management Group LLP Takes $1.04 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Wellington Management Group LLP acquired a new stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 116,392 shares of the company's stock, valued at approximately $1,037,000. Wellington Management Group LLP owned approximately 0.23% of Aura Biosciences as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Long Focus Capital Management LLC grew its holdings in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company's stock valued at $7,992,000 after buying an additional 561,766 shares in the last quarter. Levin Capital Strategies L.P. grew its holdings in shares of Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company's stock valued at $2,476,000 after purchasing an additional 216,266 shares in the last quarter. Bank of New York Mellon Corp increased its position in Aura Biosciences by 51.4% in the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company's stock worth $1,081,000 after purchasing an additional 48,549 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company's stock worth $1,892,000 after purchasing an additional 41,711 shares during the last quarter. Finally, State Street Corp raised its stake in Aura Biosciences by 3.7% during the third quarter. State Street Corp now owns 754,803 shares of the company's stock valued at $6,725,000 after purchasing an additional 26,841 shares in the last quarter. 96.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on AURA. BTIG Research boosted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, October 18th. Evercore ISI upgraded Aura Biosciences to a "strong-buy" rating in a research report on Monday, September 16th. Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a research note on Monday, September 9th. Cowen reiterated a "buy" rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, JMP Securities raised their price target on Aura Biosciences from $19.00 to $23.00 and gave the stock a "market outperform" rating in a research report on Friday, September 13th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $23.00.

Aura Biosciences Trading Up 1.1 %

Shares of NASDAQ AURA traded up $0.09 during midday trading on Friday, hitting $8.20. The company's stock had a trading volume of 612,493 shares, compared to its average volume of 182,930. Aura Biosciences, Inc. has a 12-month low of $6.63 and a 12-month high of $12.38. The firm has a market cap of $409.60 million, a P/E ratio of -4.74 and a beta of 0.26. The business's 50 day moving average is $9.70 and its two-hundred day moving average is $8.76.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.02. On average, analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the sale, the chief technology officer now directly owns 121,132 shares of the company's stock, valued at $1,193,150.20. The trade was a 5.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Janet Jill Hopkins sold 11,822 shares of the company's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the sale, the insider now owns 151,693 shares of the company's stock, valued at $1,419,846.48. This represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 79,081 shares of company stock valued at $891,353 in the last 90 days. Company insiders own 5.40% of the company's stock.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.